טוען...
Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab
INTRODUCTION: Patients with systemic lupus erythematosus (SLE) with B-lymphocyte stimulator (BLyS) levels ≥ 2 ng/mL are at increased risk of flare. A regression analysis was undertaken to identify routine clinical measures that correlate with BLyS ≥ 2 ng/mL. Efficacy and safety of belimumab 10 mg/kg...
שמור ב:
| הוצא לאור ב: | Lupus |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4785993/ https://ncbi.nlm.nih.gov/pubmed/26385220 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0961203315604909 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|